| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Natural killer cell-based immunotherapies for colorectal cancer: Current strategies, challenges, and future perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xiao-Jun Zhang, Yan Yu, Jing-Yu Li, Yu-Zhu Yan, Sha-Sha Jiang, Yi Zhang, Qin Fei, Yi-Ran Zhang, Yong-Xin Zhao, Lei Guo, Jing Lv and He-Ping Zhao |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Shaanxi Natural Science Foundation of China |
2025JC-YBMS-916 |
| Xi’an Municipal Health Commission of China |
2023ms11 |
|
| Corresponding Author |
Jing Lv, MD, Department of Clinical Laboratory, Honghui Hospital, Xi’an Jiaotong University, No. 555 Youyi East Road, Xi’an 710054, Shaanxi Province, China. lvjing-1219@163.com |
| Key Words |
Natural killer cells; Colorectal cancer; Immunotherapy; Immunosuppression; Tumor microenvironment |
| Core Tip |
Natural killer (NK) cell-based immunotherapy represents a breakthrough approach for treating colorectal cancer (CRC), particularly for microsatellite-stable tumors resistant to conventional treatments. Currently employed strategies, including cytokine therapy, checkpoint inhibition, and chimeric antigen receptor-NK cell therapy, show promise in CRC treatment, but manufacturing challenges and the immunosuppressive tumor microenvironment limit their efficacy. Emerging solutions combining gene-editing, nanotechnology, and personalized approaches may overcome these barriers, positioning NK cell therapy as a transformative CRC treatment modality. |
| Publish Date |
2025-09-05 06:36 |
| Citation |
<p>Zhang XJ, Yu Y, Li JY, Yan YZ, Jiang SS, Zhang Y, Fei Q, Zhang YR, Zhao YX, Guo L, Lv J, Zhao HP. Natural killer cell-based immunotherapies for colorectal cancer: Current strategies, challenges, and future perspectives. <i>World J Gastroenterol</i> 2025; 31(34): 110051</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i34/110051.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i34.110051 |
